Search
ProMIS Neurosciences Inc
PMNAdd to Watchlist
13.350USD
-0.100-0.74%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
119.72MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of ProMIS Neurosciences Inc is 8.33, ranking 137 out of 387 in the Biotechnology & Medical Research industry. The average price target is 112.50, with a high of 237.50 and a low of 75.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
35.500
Target Price
+163.94%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
ProMIS Neurosciences Inc
PMN
6
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is ProMIS Neurosciences Inc's price target?
Analysts forecast that ProMIS Neurosciences Inc's price target is USD 112.50, with the highest forecast at USD 237.50 and the lowest forecast at USD 75.00.
How have ProMIS Neurosciences IncPMN's recent earnings per share performed?
The market expectation was USD -1.26, while ProMIS Neurosciences IncPMN's earnings per share (EPS) for the previous quarter was USD -4.14. EPS for the next quarter is expected at USD -1.44.
What is the analyst rating for ProMIS Neurosciences Inc?
Based on the ratings of ProMIS Neurosciences Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.